|
|
Our objective is to bring therapeutics to HD patients as quickly as possible. To do that requires sharing research results among HD investigators. It also requires a balance between facilitating scientific innovation and encouraging industrial investment in HD drug development (by creating intellectual property).
These principles guide the terms of CHDI, Inc. and High Q research contracts:
- Results should be made available to other HD investigators as quickly as possible while respecting the investigator's interest in publication.
- Inventions should be patented only if doing so would enhance the timeliness and availability of HD therapeutic products.
- Patents should not be asserted against any person practicing the inventions for the purpose of HD research.
- The primary reason for commercializing patents in the HD field is to make therapeutic products available to HD patients on a fair and timely basis.
For more information about CHDI, Inc. and High Q intellectual property policies and research contracts, please contact: David Rankin
(
)
|
|
